Beijing, China

Xuzhang Lu

This inventor holds 1 USPTO granted patent. Top assignee: Beijing Normal University. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Molecular Typing by Xuzhang Lu

Introduction

Xuzhang Lu is an accomplished inventor based in Beijing, China. He has made significant contributions to the field of molecular typing, particularly in relation to multiple myeloma. His innovative work has the potential to enhance the understanding and treatment of this complex disease.

Latest Patents

Xuzhang Lu holds a patent titled "Molecular typing of multiple myeloma and application." This patent discloses a product that includes a substance for obtaining or detecting 97 gene expressions in multiple myeloma patients. Additionally, it features an apparatus designed to operate a multiple myeloma Bayesian classifier. The invention identifies a gene module co-expressed with the MCL1 gene, which helps distinguish molecular subtypes of multiple myeloma that exhibit different prognoses and sensitivities to bortezomib.

Career Highlights

Throughout his career, Xuzhang Lu has focused on advancing the understanding of multiple myeloma through innovative research and development. His work has garnered attention for its potential to improve patient outcomes and tailor treatment strategies based on molecular characteristics.

Collaborations

Xuzhang Lu has collaborated with notable colleagues, including Xiaolong Fan and Ayaz Ali Samo. These partnerships have contributed to the depth and breadth of his research, fostering a collaborative environment that enhances innovation.

Conclusion

Xuzhang Lu's contributions to molecular typing in multiple myeloma represent a significant advancement in the field. His patent and collaborative efforts highlight the importance of innovation in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…